Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 427Neoplasms, Plasma Cell 68Lymphoma, Mantle-Cell 66Lymphoma 65Recurrence 64Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Neoplasms 24Carcinoma, Non-Small-Cell Lung 24Immunoglobulin Light-chain Amyloidosis 23Leukemia 21Hodgkin Disease 17Lymphoma, B-Cell 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 13Lymphoma, Large-Cell, Anaplastic 13Hematologic Neoplasms 13Immunoblastic Lymphadenopathy 12Breast Neoplasms 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Congenital Abnormalities 11

Interventions

Dexamethasone 4XENP 1595 2Electroencephalography 2selinexor 1pomalidomide 1ixazomib 1fasudil 1birtamimab 1UE2343 1Telemedicine 1Tablets 1Standard of Care 1Rosiglitazone 1Propofol 1Positron-Emission Tomography 1Methods 1Melphalan 1Mass Screening 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hypnosis 1Hormones 1Exercise 1Ethanol 1Donepezil 1Cyclophosphamide 1Control Groups 1Calcium Dobesilate 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Alzheimer Disease × Bortezomib × Clear all
NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡